ALFA Finder| Revenue growth | 10.6% YoY in Q3 FY26 |
|---|---|
| Margins | Gross margin 58.1% (up 184bps); EBITDA margin 21.3% (up 217bps) |
| Order book | US order book exceeds $220 million |
| Demand visibility | Strong US order book and seasonal uptick in cough/cold |
| Management confidence | High; optimistic on US market dynamics and UK recovery |
Growth
Q3 Revenue grew 10.6% YoY; PAT increased 8.2% to ₹113.7cr. 9M FY26 Revenue up 9.4% YoY.
Outlook
Targets ₹4,000cr revenue by FY28; R&D spend 2.5-3% of sales; actively pursuing European acquisitions; Capex ₹50-60cr.
Risks
Price erosion in UK/US Rx segments; macroeconomic challenges in ROW markets; rising employee costs due to new labor codes.
Earnings Call filed with BSE, NSE: MARKSANS. Summary written with AI assistance from the document.
Marksans Pharma Ltd: key numbers
- Share price
- ₹308.30
- Market cap
- ₹13,973 Cr
- Revenue (annual)
- ₹2,951 Cr
- Net profit (annual)
- ₹417.9 Cr
- P/E (TTM)
- 25.0×Sector 43.8×
- Promoter holding
- 43.87%+0.00% QoQ
- FII holding
- 19.06%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Marksans Pharma Ltd
All →Marksans Pharma Earnings Call Transcript: Key Takeaways
Headline growth is strong: revenue up 30.5% to ₹940 Cr and EBITDA margin 22.8%, above the 21–22% guide. Sequentially, margin, gross margin and PAT all fell, and growth is partly acquired.
Marksans Pharma Employee Stock Options
Marksans Pharma allotted 56,250 equity shares to employee stock option grantees under its 2024 scheme. Shares were issued on exercise of vested options.
Marksans Pharma Results Update
Marksans Pharma reported Q2FY27 revenue of ₹940 crore and H1FY27 PAT of ₹303 crore. EBITDA grew 48% to a record ₹214 crore in the quarter.
Marksans Pharma Investor Presentation: Key Takeaways
Q2FY27 revenue ₹940cr (+30.5% YoY), EBITDA ₹214cr at 22.8% margin (+274bps), PAT ₹143.5cr (+44.8%). H1 PAT ₹303cr; net cash ₹1,095cr; Europe front-end being built.
Marksans Pharma Q2 FY27 Results: Net Profit ₹143.5 Cr, Up 44.8% YoY
Marksans Pharma Ltd reported revenue from operations of ₹940.2 Cr (+30.5% YoY) and net profit of ₹143.5 Cr (+44.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹143.5 Cr · +44.8% YoY
Marksans Pharma Board Meeting Date
Marksans Pharma scheduled its Board meeting for November 4, 2026, to approve Q1/H1 unaudited results. No material decision has been taken yet.